{"title":"Efficacy of Qianlie Shutong Capsule in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Single-Centre Retrospective Study.","authors":"Chaofei Zhao, Zhonggui Hu, Xinglin Ping","doi":"10.56434/j.arch.esp.urol.20257807.116","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological condition affecting men's health. This study aims to investigate the clinical efficacy of Qianlie Shutong (QLST) capsule in the treatment of CP/CPPS.</p><p><strong>Methods: </strong>The medical records of patients with CP/CPPS who were admitted to our hospital from January 2023 to January 2024 were retrospectively analysed. They were divided into observation and control groups according to treatment modality received. The control group received levofloxacin (0.5 g, qd) in combination with tamsulosin hydrochloride (0.2 mg, qd). The observation group received an additional supplementation of QLST capsule (0.4 g, tid) alongside the treatment administered to the control group. Both groups underwent treatment for 28 days. Baseline data and clinical outcomes were compared between the groups, including the National Institute of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), maximum urine flow rate (Qmax), urine volume (UV), prostate-specific extracellular vesicle protein (PSEP) and International Index of Erectile Function-15 (IIEF-15).</p><p><strong>Results: </strong>A total of 117 patients were enrolled in this study, comprising 60 in the observation group and 57 in the control group. No significant differences in baseline characteristics were found between the two groups (<i>p</i> > 0.05). Before intervention, no significant differences in NIH-CPSI, Qmax, UV, PSEP and IIEF-15 were found between the two groups (<i>p</i> > 0.05). Following intervention, both groups exhibited significant reductions in NIH-CPSI and PSEP, and the levels in the observation group were lower than those in the control group (<i>p</i> < 0.05). Qmax, UV and IIEF-15 increased in both groups, and the levels in the observation group were higher than those in the control group (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>This study demonstrates that QLST effectively alleviates the clinical symptoms in patients with CP/CPPS, reduces PSEP levels and improves erectile function, supporting its clinical application.</p>","PeriodicalId":48852,"journal":{"name":"Archivos Espanoles De Urologia","volume":"78 7","pages":"877-883"},"PeriodicalIF":0.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos Espanoles De Urologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.56434/j.arch.esp.urol.20257807.116","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological condition affecting men's health. This study aims to investigate the clinical efficacy of Qianlie Shutong (QLST) capsule in the treatment of CP/CPPS.
Methods: The medical records of patients with CP/CPPS who were admitted to our hospital from January 2023 to January 2024 were retrospectively analysed. They were divided into observation and control groups according to treatment modality received. The control group received levofloxacin (0.5 g, qd) in combination with tamsulosin hydrochloride (0.2 mg, qd). The observation group received an additional supplementation of QLST capsule (0.4 g, tid) alongside the treatment administered to the control group. Both groups underwent treatment for 28 days. Baseline data and clinical outcomes were compared between the groups, including the National Institute of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), maximum urine flow rate (Qmax), urine volume (UV), prostate-specific extracellular vesicle protein (PSEP) and International Index of Erectile Function-15 (IIEF-15).
Results: A total of 117 patients were enrolled in this study, comprising 60 in the observation group and 57 in the control group. No significant differences in baseline characteristics were found between the two groups (p > 0.05). Before intervention, no significant differences in NIH-CPSI, Qmax, UV, PSEP and IIEF-15 were found between the two groups (p > 0.05). Following intervention, both groups exhibited significant reductions in NIH-CPSI and PSEP, and the levels in the observation group were lower than those in the control group (p < 0.05). Qmax, UV and IIEF-15 increased in both groups, and the levels in the observation group were higher than those in the control group (p < 0.05).
Conclusions: This study demonstrates that QLST effectively alleviates the clinical symptoms in patients with CP/CPPS, reduces PSEP levels and improves erectile function, supporting its clinical application.
期刊介绍：
Archivos Españoles de Urología published since 1944, is an international peer review, susbscription Journal on Urology with original and review articles on different subjets in Urology: oncology, endourology, laparoscopic, andrology, lithiasis, pediatrics , urodynamics,... Case Report are also admitted.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
